Bepotastine besilate for the treatment of perennial allergic rhinitis

References

• Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988–1994. J Allergy Clin Immunol. 2010;126(4):778.
   PubMed Web of Science ®Google Scholar
• Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc. 2001;22(4):185.
   PubMed Web of Science ®Google Scholar
• Katelaris CH, Lee BW, Potter PC, et al. Preva-lence and diversity of allergic rhinitis in regions of the world beyond Europe and North America. Clin Exp Allergy. 2012;42:186–207.
   PubMed Web of Science ®Google Scholar
• Wallace DV, Dykewicz MS, Bernstein DI, et al. Joint task force on practice, American academy of allergy, asthma&immunology, American college of allergy, asthma and immunology, joint council of allergy, asthma and immunology. Diagnosis management rhinitis: updated practice parameter J Allergy Clin Immunol. 2008;122(2 Suppl):S1.
   PubMed Web of Science ®Google Scholar
• Maspero J, Lee BW, Katelaris CH, et al. Quality of life and control of allergic rhinitis in patients from regions beyond western Europe and the United States. Clin Exp Allergy. 2012 Dec;42(12):1684–1696.
   PubMed Web of Science ®Google Scholar
• Vandenplas O, Vinnikov D, Blanc PD, et al. Impact of rhinitis on work productivity: a systematic review. J Allergy Clin Immunol Pract. 2018;6(4):1274–1286.e9.
   PubMed Web of Science ®Google Scholar
• Seidman MD, Gurgel RK, Lin SY, et al. Mims, James Whit W; Omole, Folashade S; Reddy, William D; Wallace, Dana V; Walsh, Sandra A; Warren, Barbara E; Wilson, Meghan N; Nnacheta, Lorraine C. Clinical practice guideline: Allergic Rhinitis Int Forum Allergy Rhinol. 2018 Feb;8(2):108–352.
   PubMedGoogle Scholar
• Brozek et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016. revision. J Allergy Clin Immunol. 2017 Oct;140(4):950–958.
   PubMed Web of Science ®Google Scholar
• van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, Fokkens WJ, Howarth PH, Lund V, Malling HJ, Mygind N, Passali D, Scadding GK, Wang DY. Consensus statement on the treatment of allergic rhinitis. Eur Acad Allergol Clin Immunology. Allergy. 2000;55(2):116.
   Google Scholar
• Lyseng-Williamson KA. Oral bepotastine: in allergic disorders. Drugs. 2010 Aug 20;70(12):1579–1591.
   PubMed Web of Science ®Google Scholar
• Williams JI, Gow JA, Klier SM. McCue, Shannon L; Salapatek, Anne Marie F; McNamara, Timothy R. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin. 2010 Oct;26(10):2329–2338.
   PubMed Web of Science ®Google Scholar
• Ukai K, Takeuchi M, Masuda S, et al. Clinical pharmacological study of antiallergic agent, TAU-284 (bepotastine besilate): the effect on counting of eosinophils in nasal discharge and the patency improvement of nasal cavity[in Japanese]. Rinsho Iyaku. 1997;13(5):1401–1412.
   Google Scholar
• Sakai A, Kikuchi M, Yato N, et al. Inhibitory effect of bepotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice. Arzneimittelforschung. 1997 Aug;47(8):954–958.
   PubMed Web of Science ®Google Scholar
• Bepreve™ (bepotastine besilate ophthalmic solution) 1.5% prescribing information. ISTA pharmaceuticals®. [cited 2018 Apr 9]. Available from: https://www.accesdata.fda.gov/drugsatfda_docs/nda/2009/022288s000_Lbl.pdf
   Google Scholar
• Talion® tablets (bepotastine besilate): product information. Osaka: Tanabe Seiyaku Co., Ltd; 2006.
   Google Scholar
• Yokota H, Mizuuchi H, Maki T, et al. Phase I study of TAU-284: single oral administration in healthy male volunteers [in Japanese]. Rinsho Iyaku. 1997;13(5):1137–1153.
   Google Scholar
• Kadosaka T, Shiraishi K, Mizuuchi H, et al. Phase I study of TAU-284: repeated oral administration in healthy male volunteers [in Japanese]. Rinsho Iyaku. 1997;13(5):1155–1168.
   Google Scholar
• Kumagai Y, Uchiumi M, Murasaki M, et al. Pharmacokinetics study of TAU-284 in elderly volunteers [in Japanese]. Rinsho Iyaki. 1997;13(5):1169–1185.
   Google Scholar
• Kawashima K, Sakai M, Takatsuka S, et al. Clinical pharmacokinetic study of Talion tablet (bepotastine besilate) in nephropathic patients (post-marketing clinical trial) [in Japanese]. Rinsho Iyaku. 2003;19(6):637–648.
   Google Scholar
• Takahashi H, Ishida-Yamamoto A, Iizuka H. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. Clin Exp Dermatol. 2004 Sep;29(5):526–532.
   PubMed Web of Science ®Google Scholar
• Tashiro M, Duan X, Kato M, et al. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin. Br J Clin Pharmacol. 2008 Jun;65(6):811–821.
   PubMed Web of Science ®Google Scholar
• Baba S, Sakakura Y, Iwata S, et al. Early phase II study of TAU-284 (bepotastine besilate) on perennial allergic rhinitis [in Japanese]. Rinsho Iyaku. 1997;13(5):1217–1235.
   Google Scholar
• Baba S, Takasaki T, Baba K, et al. Late phase II clinical study of TAU-284 for perennial allergic rhinitis: dose finding study by the double-blind method [in Japanese]. Rinsho Iyaku. 1997;13(5):1259–1286.
   Google Scholar
• Baba S, Takasaka T, Baba K, et al. Clinical trial of TAU-284 (bepotastine besilate) on perennial allergic rhinitis: a doubleblind study in comparison with terfenadine [in Japanese]. Rinsho Iyaku. 1997;13(5):1307–1335.
   Google Scholar
• Baba S. Post-marketing surveillance study of Talion® tablets on pediatric allergic rhinitis [in Japanese]. Rinsho Iyaku. 2002;18(12):1371–1387.
   Google Scholar
• Baba K. Results from post-marketing surveillance studies of Talion® tablets (bepotastine besilate) in patients with allergic rhinitis [in Japanese]. J New Rem Clin. 2007 Feb 10;56(2 Suppl.):10–33.
   Google Scholar
• Okubo K, Ichimura M, Koyama T, et al. Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis. Expert Opin Pharmacother. 2015;16(16):2395–2408.
   PubMedGoogle Scholar
• Baba S, Takasaka T, Baba K, et al. Long-term treatment of TAU-284 (bepotastine besilate) on perennial allergic rhinitis [in Japanese]. Rinsho Iyaku. 1997;13(5):1361–1382.
   Google Scholar
• Okubo K, Kurono Y, Ichimura K, et al. Japanese society of allergology. Japanese guidelines for allergic rhinitis 2017. Allergol Int. 2017 Apr;66(2):205–219.
   PubMed Web of Science ®Google Scholar
• Torkildsen GL, Williams JI, Gow JA, et al. Bepotastine besilate ophthalmic solutions clinical study group. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Ann Allergy Asthma Immunol. 2010 Jul;105(1):57–64.
   PubMed Web of Science ®Google Scholar